AI Article Synopsis
- Tocilizumab (TCZ) is an IL-6 inhibitor that has shown effectiveness in treating donor-specific antibodies (DSA) and chronic antibody-mediated rejection (AMR) in kidney transplant patients, but its application in lung transplants was previously unexplored.
- A study compared 9 lung transplant patients treated with TCZ for AMR to 18 patients treated without TCZ, finding that TCZ led to better DSA clearance, reduced DSA recurrence, and lower graft failure rates.
- The side effects such as infusion reactions and infections were similar in both groups, indicating the potential for TCZ in treating pulmonary AMR and supporting further research into randomized controlled trials for IL-6 inhibitors.
Article Abstract
Tocilizumab (TCZ), an IL-6 inhibitor, has shown promise in the treatment of donor-specific antibodies (DSA) and chronic antibody-mediated rejection (AMR) in renal transplant recipients. However, its use in lung transplantation has not been described. This retrospective case-control study compared AMR treatments containing TCZ in 9 bilateral lung transplant recipients to 18 patients treated for AMR without TCZ. Treatment with TCZ resulted in more clearance of DSA, lower recurrence of DSA, lower incidence of new DSA, and lower rates of graft failure when compared to those treated for AMR without TCZ. The incidence of infusion reactions, elevation in transaminases, and infections were similar between the 2 groups. These data support a role for TCZ in pulmonary AMR and establish preliminary evidence to design a randomized controlled trial of IL-6 inhibition for the management of AMR.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529998 | PMC |
| http://dx.doi.org/10.1016/j.healun.2023.05.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!